MiNK Therapeutics, Inc. INKT

agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to res

Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invaria

Moby summary of MiNK Therapeutics, Inc.'s Q2 2026 earnings call

MiNK Therapeutics reports encouraging initial data from its ARDS study, narrows net loss, and expands international access programs despite a tight cash position.

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor supportClinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797Launched interna

First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and lung fluid showed signals of infection control and biological changes associated with immune recovery, tissue repair and pulmonary recoveryMiNK initiated dosing immediately after regulatory clearance; a pace made possible by our therapy that ships from inventory, with no apheresis, patient-specific m

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and p

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.vir

First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapiesPreliminary data expected in the second half of 2026 NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneerin

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides immitis NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapi

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Moby summary of MiNK Therapeutics, Inc.'s Q1 2026 earnings call

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic collaborations, while navigating financial hurdles and development risks.